PCM
GPCR icon

Pentwater Capital Management’s Structure Therapeutics GPCR Stock Holding History

Pentwater Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-245,000
Closed -$11.8M – 105
2026
Q1 		$11.8M Buy
+245,000
New +$16.8M 0.06% 60

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pentwater Capital Management's GPCR Position: Q2 2026 in Review

Pentwater Capital Management sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 245,000 shares — an estimated $11.8M sold.

Pentwater Capital Management first reported a position in GPCR in Q1 2026 and held it in 1 quarter. The position peaked at $11.8M in Q1 2026. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Pentwater Capital Management reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pentwater Capital Management sold 245,000 Structure Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Pentwater Capital Management first reported a position in Structure Therapeutics in Q1 2026 and held it in 1 quarter.
  • Pentwater Capital Management's Structure Therapeutics position peaked at $11.8M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Pentwater Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.